A recent study suggests that the dopamine D3 receptor partial agonist BP 897 prevents cocaine-seeking behavior in rats, and this may lead to new approaches to study and treat drug addiction.

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Tavapadon is the first and only selective D1/D5 receptor partial agonist under investigation for Parkinson’s and is being studied both as a monotherapy and adjunctive therapy to levodopa ...